000163660 001__ 163660
000163660 005__ 20250415100046.0
000163660 0247_ $$2doi$$a10.14283/jpad.2022.2
000163660 0247_ $$2pmid$$apmid:35098976
000163660 0247_ $$2ISSN$$a2274-5807
000163660 0247_ $$2ISSN$$a2426-0266
000163660 0247_ $$2altmetric$$aaltmetric:126476219
000163660 037__ $$aDZNE-2022-00406
000163660 041__ $$aEnglish
000163660 082__ $$a610
000163660 1001_ $$aMourtzi, N.$$b0
000163660 245__ $$aAssociation between 9p21-23 Locus and Frailty in a Community-Dwelling Greek Population: Results from the Hellenic Longitudinal Investigation of Ageing and Diet.
000163660 260__ $$aCham$$bSpringer International Publishing$$c2022
000163660 3367_ $$2DRIVER$$aarticle
000163660 3367_ $$2DataCite$$aOutput Types/Journal article
000163660 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1744620737_16032
000163660 3367_ $$2BibTeX$$aARTICLE
000163660 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163660 3367_ $$00$$2EndNote$$aJournal Article
000163660 520__ $$aFrailty is a complex geriatric syndrome arising from a combination of genetic and environmental factors and is associated with adverse health outcomes and mortality. A recent study reported an association between variants of the 9p21-23 locus, associated with a number of age-related disorders, including Alzheimer's disease (AD), and frailty. Frailty has been associated with increased risk of developing AD and it has been proposed that frailty burden may modify AD clinical presentation. In view of the overlapping genetic architecture between the two disorders, it is noteworthy to conduct studies to uncover risk variants that contribute to both AD and frailty. The purpose of this study is to test the reproducibility of the association of 9p21-23 locus with frailty in a population that is ethnically different from previous work and in the context of multidimensional definitions of frailty that will allow us to examine the potential impact to domains pertaining to AD pathology.We operationalized frailty according two definitions and the corresponding instruments, the Frailty Index (FI) and the Tilburg Frailty Indicator (TFI) and we determined genotypes of eight alleles previously identified as risk increasing for frailty in 1172 community-dwelling older participants (57% females) from the HELIAD study with a mean age of 74 years old. We cross-sectionally investigated the association between risk alleles and frailty, as well as with specific components of each definition using linear regression analyses adjusted for age, sex and years of education.Compared to non-carriers, carriers of rs7038172 C risk allele, were associated with a higher FI Score (β=0.089, p=0.002). Similarly, we found a positive association between the presence of at least one rs7038172 C variant and TFI score (β=0.053, p=0.04). Moreover, the rs7038172 variant was associated, irrespectively of dementia status, with the memory and psychological domain of FI and TFI, respectively.Our study confirms the association of the rs7038172 C allele with the frailty syndrome in a Greek population and in the context of multidimensional definitions of frailty. Furthermore, we report novel associations between this allele and the memory domain of FI and the psychological domain of TFI, that includes memory problems on its components. Given that frailty burden has been shown to modify the AD clinical presentation, it is likely that rs7038172 C allele may accelerate the transition of AD or frailty to dementia Overall, our study corroborates the role of the 9p21-23 region in frailty development and draw potential links with AD pathology.
000163660 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163660 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163660 650_7 $$2Other$$a9p21-23 locus
000163660 650_7 $$2Other$$aAlzheimer
000163660 650_7 $$2Other$$aFrailty
000163660 650_7 $$2Other$$agenetics
000163660 7001_ $$aHatzimanolis, A.$$b1
000163660 7001_ $$aXiromerisiou, G.$$b2
000163660 7001_ $$aNtanasi, E.$$b3
000163660 7001_ $$aGeorgakis, M. K.$$b4
000163660 7001_ $$0P:(DE-2719)2812825$$aRamirez, A.$$b5$$udzne
000163660 7001_ $$aHeilmann-Heimbach, S.$$b6
000163660 7001_ $$aGrenier-Boley, B.$$b7
000163660 7001_ $$aLambert, J. C.$$b8
000163660 7001_ $$aYannakoulia, M.$$b9
000163660 7001_ $$aKosmidis, M.$$b10
000163660 7001_ $$aDardiotis, E.$$b11
000163660 7001_ $$aHadjigeorgiou, G.$$b12
000163660 7001_ $$aSakka, P.$$b13
000163660 7001_ $$aScarmeas, N.$$b14
000163660 773__ $$0PERI:(DE-600)2782183-3$$a10.14283/jpad.2022.2$$gVol. 9, no. 1, p. 1 - 9$$n1$$p77-85$$tThe journal of prevention of Alzheimer's disease$$v9$$x2274-5807$$y2022
000163660 8564_ $$uhttps://pub.dzne.de/record/163660/files/DZNE-2022-00406.pdf$$yOpenAccess
000163660 8564_ $$uhttps://pub.dzne.de/record/163660/files/DZNE-2022-00406.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163660 909CO $$ooai:pub.dzne.de:163660$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000163660 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000163660 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163660 9141_ $$y2022
000163660 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000163660 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000163660 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000163660 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJPAD-J PREV ALZHEIM : 2021$$d2022-11-12
000163660 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000163660 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-02-03$$wger
000163660 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000163660 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163660 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJPAD-J PREV ALZHEIM : 2021$$d2022-11-12
000163660 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000163660 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000163660 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000163660 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x0
000163660 980__ $$ajournal
000163660 980__ $$aVDB
000163660 980__ $$aUNRESTRICTED
000163660 980__ $$aI:(DE-2719)1011101
000163660 9801_ $$aFullTexts